FEIBA (factor eight inhibitor bypassing activity; Shire) is a bypassing agent derived from human plasma. The constituents of FEIBA include factors II, IX, and X (mainly in the inactivated form) and factor VII (mainly in the activated form). FEIBA is able to restore hemostasis via multiple mechanisms including thrombin generation on the platelet surface. As a bypassing agent, FEIBA is indicated for both hemophilia A and B, and is prescribed in patients who develop inhibitors against factors VIII or IX. The current formulation of FEIBA is both nanofiltered and vapor heated to reduce the risk of viral transmission.
Shire now manufactures and markets FEIBA following its acquisition of Baxalta in June 2016. FEIBA was previously developed and first commercialized by Baxter, with its first approval in 1986.
LIST OF FIGURES
9 Figure 23: Alprolix for hemophilia – SWOT analysis
10 Figure 24: Datamonitor Healthcare’s drug assessment summary of Alprolix for hemophilia
12 Figure 25: Datamonitor Healthcare’s drug assessment summary of Alprolix for hemophilia
LIST OF TABLES
6 Table 1: FEIBA drug profile
7 Table 2: FEIBA pivotal trial data in hemophilia
13 Table 3: FEIBA sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2016–25
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.